Recent News

Patterns of PD-L1 Expression in NSCLC Harboring Driver Oncogene Mutations

Adding Durvalumab to Neoadjuvant Chemotherapy in Stage IIIA (N2) NSCLC

Update From EV-103: Enfortumab Vedotin-ejfv Plus Pembrolizumab for Advanced Urothelial Carcinoma

Pembrolizumab Combination Receives FDA Approval in Triple-Negative Breast Cancer

Can Nephrectomy Prior to Immunotherapy Improve Survival in Renal Cell Carcinoma?

Subcutaneous Use of BCMA-CD3 Bispecific Monoclonal Antibody in Myeloma

Can Adding Cetuximab to Afatinib Improve Outcomes in NSCLC?

Adding Daratumumab to Combination Therapy for Newly Diagnosed Multiple Myeloma

Choice of Platinum in First Line Treatment of Advanced Urothelial Carcinoma in the Era of Second-Line Immunotherapy

Lenvatinib Plus Pembrolizumab in Renal Cell Carcinoma: Phase IB/II Trial Results

Nivolumab Alone and in Combination Therapy for Non–Clear Cell Kidney Cancer

First-in-Human Trial of Bispecific IgG4 Antibody for Multiple Myeloma

Enfortumab Vedotin-ejfv Receives FDA Approval for Advanced Urothelial Carcinoma

Pooled Analysis of HER2-Targeting Antibody-Drug Conjugate in Metastatic Breast Cancer

FDA Approves Daratumumab and Hyaluronidase-fihj Combination Therapy for Multiple Myeloma

Perioperative Use of Cemiplimab Under Study in Cutaneous Squamous Cell Carcinoma

Updated Survival Outcomes From PACIFIC Trial of Immunotherapy for Stage III Lung Cancer

Phase II Study of Bipolar Androgen Therapy and Nivolumab in Prostate Cancer

EHA2021: ANDROMEDA Trial Update Supports Daratumumab-Based Therapy for AL Amyloidosis

FDA Expands Pembrolizumab Label for Locally Advanced Cutaneous Squamous Cell Carcinoma

Early Results With PSMA-Targeting T-Cell Engager in Metastatic Prostate Cancer

EHA2021: CLL14 Follow-up Supports Use of Venetoclax Plus Obinutuzumab

ASCO2021: CARTITUDE-1 Update on Ciltacabtagene Autoleucel for Resistant Myeloma

Does Pembrolizumab Plus Chemotherapy–Induced Pneumonitis Impact Survival Outcomes in NSCLC?

Patient With Breast Cancer Successfully Treated With Immunotherapy in Thailand Hospital

ASCO 2021: Converting Peripheral Blood Mononuclear Cells Into Autologous Cellular Therapy for CLL

ASCO 2021: Phase II Study of Domatinostat Plus Avelumab for Merkel Cell Carcinoma

ASCO 2021: LAG-3 Protein Plus Pembrolizumab Under Study in Metastatic Lung Cancer

Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: Changing the Treatment Game

ASCO 2021: Early Trial Update of Teclistamab in Resistant Multiple Myeloma

EHA2021: CLL14 Follow-up Supports Use of Venetoclax Plus Obinutuzumab

FDA Brief: Teclistamab Receives Breakthrough Therapy Designation for Resistant Myeloma

ASCO 2021: EGFR- and MET-Based Biomarkers of Resistance to Therapy for Lung Cancer

AXL Inhibitor Bemcentinib Receives Fast Track Designation in Combination Therapy for Lung Cancer

ASCO 2021: INDUCE-1 Trial of Feladilimab Plus Pembrolizumab in Urothelial Carcinoma

EHA2021: Targeting BCMA in Early-Phase Study in Resistant Myeloma

ASCO 2021: Early-Phase Results of Anti-CLL1–Based CAR T-Cell Therapy in Children With AML

ASCO 2021: Combination of HDAC Inhibitor and Pembrolizumab in Advanced Skin Cancer

ASCO 2021: Durvalumab-Based Therapy for Ultra-High–Risk Newly Diagnosed Myeloma

ASCO 2021: Neoadjuvant Therapy and Transurethral Resection of Bladder Cancer

ASCO 2021: 4-Year Update of ELEVATE-TN Trial of Acalabrutinib Regimens in CLL

Is KRAS Status Linked to Response to Immunotherapy for Advanced Lung Cancer?

ASCO 2021: Post Hoc Subgroup Analyses With Avelumab in Advanced Urothelial Carcinoma

ASCO 2021: KarMMa Update of BCMA-Directed CAR T-Cell Therapy for Refractory Myeloma

ASCO 2021: Adjuvant Durvalumab Treatment for Triple-Negative Breast Cancer

EHA2021: Iberdomide-Based Regimens for Relapsed or Refractory Multiple Myeloma

ASCO 2021: Cemiplimab-rwlc and Quality of Life in Patients With Locally Advanced Skin Cancer

ASCO 2021: Impact of Lenvatinib-Based Therapy on Quality of Life in Renal Cell Carcinoma

ASCO 2021: 2-Year Follow-up With Nivolumab/Ipilimumab Plus Chemotherapy for Advanced Lung Cancer

ASCO 2021: Can Live Bacterial Product Enhance Response to Immunotherapy in Metastatic Renal Cell Cancer?

EHA2021: Phase III GLOW Trial of Ibrutinib and Venetoclax as First-Line CLL Therapy

EHA2021: MAIA Trial Update on Daratumumab-Based Therapy for Newly Diagnosed Myeloma

ASCO 2021: KEYNOTE-052 Survival Update on First-Line Pembrolizumab in Advanced Urothelial Cancer

ASCO 2021: Interim Analysis of CASSIOPEIA Trial of Daratumumab Maintenance in Myeloma

ASCO 2021: Health-Related Quality of Life With Pembrolizumab for Cutaneous Squamous Cell Carcinoma

ASCO 2021: Bladder-Sparing Combination Therapy Under Study in Muscle-Invasive Urothelial Cancer

ASCO 2021: 42-Month Follow-up of Pembrolizumab Plus Axitinib in Advanced Clear Cell Kidney Cancer

ASCO 2021: Survival Outcomes With De-escalated Neoadjuvant Treatment of Early Breast Cancer

Australian Researchers Explore Immunotherapy-Related Concepts in Squamous Cell Skin Cancer

ASCO 2021: Surgical Outcomes With Neoadjuvant Nivolumab Plus Chemotherapy in NSCLC